|
|
|
|
|
|
|
| CA
19-9 Test, Blood |
| |
|
CA 19-9 antigen, serum |
| This is one of the "mucin-type glycoproteins" carbohydrate
(cancer) antigens which may circulate in the blood of patients
with pancreatic and other adenocarcinomas...casually considered
to be a "pancreatic cancer marker". An ovarian
cancer (OC19-9) cell line is cultivated and maintained to produce
cancer cells which are injected into mice to produce antibodies
against the OC19-9 cells. The murine (mouse) lymphocytes are harvested
and grown to produce the antibodies at commercial volumes2.It
can be helpful in the initial evaluation of a newly discovered
mass of the pancreas. If this test is really high in such a case,
then the odds are very high that it is a non-resectable cancer.
One would then perform a fine-needle biopsy to prove the malignant
diagnosis. Whether or not to perform exploratory surgery for the
possibility of performing a Whipple procedure to remove the tumor
would depend on many additional factors. |
Conditions Causing Elevations (>40U/mL) of
this Marker:
- pancreatic cancer
72-79%
- but, 200g., 6cm SCC of pancreas with clear margins but growing into
gastric wall (AJC stage IVA) preop. only 71 (nl<37)[LMC-01-4430]
- biliary cancers 67%-73%
- gastric cancers 42-62%
- colorectal cancers 19-41%; when elevated preoperatively, this
is a good follow-up marker for early evidence of recurrence
- benign multicystic
mesothelioma of peritoneum (BMMP)
- may see a moderate elevation associated with collagen diseases, diabetes mellitus, alcoholic or non-alcoholic liver disease, and acute or chronic pancreatitis & combination CA125 & CA19-9 pretty specific for advanced fibrosis or cirrhosis 4.
- other [warning]
situations wherein the level is not elevated:
- some...particularly when small and curatively resectable...pancreatic
cancers are present without elevation.
- non-adenocarcinomatous malignant tumors of the pancreas
- benign pancreatic tumors
|
PAM4 is another extra-hepatic, pancreaticobiliary antigen getting attention in late 2011 and early 20125. But, even combined with CA19-9, it does not really help that much in early detection of treatable disease. It has false positives and negatives.
|
References:
-
Seminars in Oncology, vol.
20, #3, page 255 June 1993
-
The Handbook of Clinical Pathology [text],
McKenna & Keffer, 2nd Ed., 2000.
-
Interpretation of Diagnostic Tests, Wallach,
2000, 7th Ed.
- Etxagibel A, et. al., "Drug-induced hepatitis superimposed on the presence of anti-SLA antibody: a case report", J Med Case Reports 2:25, 2008.
- Medscape commentary (PAM4) January 2012 HERE.
Synonyms:
(posted 7 April 2002; latest addition 13 February 2012)
|
|
|
© Copyright
1999 - 2006, all rights reserved, Pathology Associates Of Lexington,
P.A. |
| |